Oncoimmunology
-
Publication Venue For
- Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models.. 9:1806009. 2020
- Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.. 9:1773200. 2020
- ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer.. 9:1758003. 2020
- Metabolism in the tumor microenvironment: insights from single-cell analysis.. 9:1726556. 2020
- T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma.. 9:1749476. 2020
- Clinical characterization of colitis arising from anti-PD-1 based therapy.. 8:e1524695. 2019
- IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment.. 8:e1515058. 2019
- CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response.. 7:e1502904. 2018
- Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors.. 7:e1421891. 2018
- Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma.. 7:e1434464. 2018
- Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.. 6:e1264563. 2017
- Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade.. 6:e1349587. 2017
- Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression.. 6:e1277308. 2017
- Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling.. 6:e1305535. 2017
- Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity.. 6:e1356150. 2017
- Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.. 6:e1256527. 2017
- Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition.. 6:e1315495. 2017
- Embracing rejection: Immunologic trends in brain metastasis.. 5:e1172153. 2016
- Prioritization schema for immunotherapy clinical trials in glioblastoma.. 5:e1145332. 2016
- The tumor microenvironment disarms CD8+ T lymphocyte function via a miR-26a-EZH2 axis.. 5:e1245267. 2016
- The macrophage: Switches from a passenger to a driver during anticancer therapy.. 4:e1052929. 2015
- Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.. 4:e1026529. 2015
- TLR5 signaling, commensal microbiota and systemic tumor promoting inflammation: the three parcae of malignant progression.. 4:e1021542. 2015
- Are BiTEs the "missing link" in cancer therapy?. 4:e1008339. 2015
- Diversity index of mucosal resident T lymphocyte repertoire predicts clinical prognosis in gastric cancer.. 4:e1001230. 2015
- Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.. 4:e994374. 2015
- miR-23a blockade enhances adoptive T cell transfer therapy by preserving immune-competence in the tumor microenvironment.. 4:e990803. 2015
- Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence.. 3:e944059. 2014
- Immunological targeting of cytomegalovirus for glioblastoma therapy.. 3:e29289. 2014
- Immunovirotherapy for the treatment of glioblastoma.. 3:e27218. 2014
- Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy.. 3:e944054. 2014
- A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma. 2:1-2. 2013
- A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.. 2:e26852. 2013
- Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody.. 2:e26757. 2013
- Regulatory T cells are redirected to kill glioblastoma by an EGFRviii-targeted bispecific antibody. 2:1-2. 2013
- A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system.. 2:e23639. 2013
- Good things come in small packages: Therapeutic anti-tumor immunity induced by microRNA nanoparticles.. 1:968-970. 2012